Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Will Co-Diagnostics Stock Go to $30?

TheMotleyFool

0 0

Jason McCarthy, an analyst at Maxim Group, has raised the investment bank's rating on Co-Diagnostics (NASDAQ: CODX). Increasing sales of Co-Diagnostics' test for COVID-19 led McCarthy to upgrade the stock to a buy and give it a $30 price target.

Despite McCarthy's ambitious new price target and rating upgrade, shares of Co-Diagnostics fell about 2.5% during the first half of Wednesday's trading session. At the stock's recent price of $18.27, Maxim's new target suggests a 63% gain once the rest of the market sees the company's future in the same light as McCarthy.

Image source: Getty Images.

Source Fool.com

Like: 0

CODX

Share